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Edited by Gerrit van MeerAbstract Multidrug transporters are involved in mediating the
failure of chemotherapy in treating several serious diseases.
The archetypal multidrug transporter P-glycoprotein (P-gp) con-
fers resistance to a large number of chemically and functionally
unrelated anti-cancer drugs by mediating eﬄux from cancer
cells. The ability to eﬄux such a large number of drugs remains
a biological enigma and the lack of mechanistic understanding of
the translocation pathway used by P-gp prevents rational design
of compounds to inhibit its function. The translocation pathway
is critically dependent on ATP hydrolysis and drug interaction
with P-gp is possible at one of a multitude of allosterically linked
binding sites. However, aspects such as coupling stoichiometry,
molecular properties of binding sites and the nature of conforma-
tional changes remain unresolved or the centre of considerable
controversy. The present review attempts to utilise the available
data to generate a detailed sequence of events in the transloca-
tion pathway for this dexterous protein.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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interaction; Drug-binding1. What steps are required in an active translocation pathway?
The ability to translocate multiple substrates/drugs is shared
by many transporters, however, the underlying mechanisms
are yet to be elucidated. Multidrug transporters have been
implicated in conferring resistance to chemotherapy in cancer,
malaria and bacterial infection [1–3]. P-glycoprotein (P-gp,
ABCB1) is an archetypal multidrug transporter of the ATP
binding cassette (ABC) family and the translocation of drugs
across the plasma membrane by P-gp is a complex function
involving allosteric communication between a multiplicity of
drug binding sites and the two nucleotide binding domains
(NBDs) [4]. To fully understand the molecular mechanism of
translocation of drugs by P-gp requires identiﬁcation of the
individual steps and characterisation of the intermediate con-
formational states of the protein in the pathway. The ﬁrst
stages of the process will involve the association of drugs to
high aﬃnity binding sites and of hydrolysable nucleotide to
the NBDs. These two processes are inextricably coupled, as*Corresponding author. Fax: +44 1865 221 834.
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and the dependence of translocation on the presence of two
functional NBDs [4–7]. For P-glycoprotein, biochemical infor-
mation exists that is consistent with the structural information
derived from other ABC proteins that during the translocation
cycle the two NBDs are brought into close proximity – termed
the NBD sandwich, or closed dimer [8]. In order to generate an
eﬃcient and rapid translocation of drug it requires that the
binding sites also switch from high aﬃnity (to promote drug
association) to low aﬃnity (to promote drug dissociation),
alternately exposed to opposite sides of the bilayer. Once the
drug has been released to the extracellular environment, the
protein must be reset to the initial conformation. The resetting
phase of the translocation cycle will involve further alteration
to NBD:NBD interactions and reorientation of the TMDs to
restore high aﬃnity drug binding. Clearly the overall pathway
for drug translocation can be sub-divided into a series of inter-
mediate steps. Each one of these steps will represent transition
of the protein between distinct conformational states. The indi-
vidual conformations, or transition intermediates, are formed
by events such as: (i) association of nucleotide, (ii) dimerisation
of NBDs or (iii) release of Pi to name a few. The propensity for
transition between the conformations is governed by thermo-
dynamic considerations and each may be represented by an
equilibrium constant and DG. Each of the major steps in the
translocation cycle comprises multiple thermodynamic equilib-
ria, which may occur in distinct sequence. A proposed model
for the entire pathway leading to translocation of drug by P-
gp is shown in Fig. 1. This model, which contains multiple
chemical equilibria, will be referred to as the thermodynamic
transition model and the aim of this review is to discuss the
likely, or preferred, sequence of steps in the overall transloca-
tion pathway. This thermodynamic transition model is dis-
cussed with regard to the four key stages of translocation:
(A) loading of P-gp, (B) high to low aﬃnity switch in drug
binding sites, (C) energy utilisation and (D) resetting to the ba-
sal conformation. These individual stages (A–D) of the overall
pathway are represented by cubes within Fig. 1.2. Drug binding is required to couple the NBDs and TMDs
Fig. 2 represents a subsection of Fig. 1 and describes the
transition from basal (Hn) to drug and ATP bound (dHNATP)
protein. This transition consists of a series of chemical equilib-
ria and may in principle occur via multiple routes. However,blished by Elsevier B.V. All rights reserved.
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Fig. 1. A pharmacological model for drug translocation by P-gp. The entire translocation pathway has been depicted as a series of steps involving
conformational transitions and interactions of the protein with drug and nucleotides. Each step represents an equilibrium reaction and the model
displays all possible transitions (denoted by the straight lines). The drug binding sites within the TMD exist in the inward facing high aﬃnity (H) or
the outward facing low aﬃnity (L) conﬁgurations. The NBDs are also in equilibrium between the separate (n) and engaged (N) conformations. Drug
is denoted by ‘‘d’’ and the favoured series of transitions is depicted with the arrows and shaded transition intermediates. The starting point for the
scheme is the drug and nucleotide free protein, with disengaged NBDs and a TMD with drug binding sites in the high aﬃnity inward facing
conﬁguration (i.e., Hn). The lines containing an arrow correspond to the likely sequence of events in the translocation pathway as discussed in the
main text. The cube denoted (A) refers to the loading of P-gp with drug and nucleotide; (B) depicts the high to low aﬃnity reorientation of the drug
binding sites; (C) depicts the energy utilisation step and (D) corresponds to the resetting phase.
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of the overall path will be dictated primarily by changes in free
energy (DG) associated with individual equilibria. In this mod-
el, the basal conformation of P-gp comprises a high aﬃnity in-
ward facing drug binding site (‘H’) and the NBDs in a
‘‘disengaged’’ (open, ‘n’) conﬁguration. During the transition
to the fully loaded state, the NBDs assume close apposition
to the classical sandwich (closed) dimer conformation. There
is considerable experimental evidence to indicate that the
NBDs are brought from an open to closed dimer association
following the binding of nucleotide in a variety of ABC trans-
porters. Crystal structure data for isolated NBDs indicates
that both NBDs contribute to the binding interaction with
ATP and that the nucleotide ‘‘bridges’’ the interface of the pro-
tein dimer [9–11]. Furthermore, structures generated for the
bacterial lipid A transporter, MsbA, which is a P-gp homo-
logue, propose extraordinarily large movements of the NBDs,
including NBD dimerisation, during progression through theremid
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Fig. 2. Loading of P-gp with drug and nucleotide. A subsection of the
thermodynamic transition model that corresponds to the initial stage
of drug translocation; namely, loading of P-gp with drug and
nucleotide. ‘‘H’’ corresponds to the drug binding sites within the
TMD in the inward facing high aﬃnity conﬁguration. The NBDs are
also in equilibrium between the separate (n) and engaged (N)
conformations whilst drug is denoted by ‘‘d’’.catalytic cycle [12–14]. For P-gp, the evidence of NBD inter-
digitation is more indirect; spectroscopic investigations dem-
onstrate that the basal conformation has an initially low
ATP binding aﬃnity (Kd  0.5 mM) [15] and numerous muta-
tions within key motifs in the NBDs fail to impact signiﬁcantly
on nucleotide binding despite abrogating hydrolysis [16–19].
Such observations are consistent with a loose association of
the NBDs prior to ATP binding. This initial loose binding is
thought to eventually assume a higher aﬃnity, presumably
once the NBDs associate. Indeed, a murine P-gp isoform con-
taining the double mutation of the Walker-B proposed cata-
lytic glutamate residues (E522A/E1197A) displayed binding
constants of Kd = 9.2 lM and 38 lM to the N- and C-terminal
NBDs, respectively [20]. This increase in aﬃnity from the ini-
tial Kd = 500 lM [15] provides support for a closed NBD di-
mer. The inability to readily disrupt this conformation is
also consistent with a tight NBD association in P-gp. The asso-
ciation of ATP and movement of NBDs from open (n) to
closed (N) dimer formation are depicted by the
Hnﬁ HnATPﬁ HNATP transition sequence. This transition
can occur in the absence of drugs as illustrated by the hitherto
unexplained ability of P-gp to generate basal ATPase activity;
i.e., ATP hydrolysis in the absence of transported substrate
[21–24]. In fact, the transition sequence Hnﬁ HnATPﬁ H-
NATP is the likely sequence of events that supports basal ATP-
ase activity; although this does not preclude hydrolysis from
the disengaged conformation (i.e., HnATPﬁ HnATP) under ba-
sal conditions. The latter is unlikely to be the chosen route,
particularly given the reported similarity of Km(ATP) obtained
for basal and drug stimulated ATPase activities [5,6,23,25].
The stoichiometric amount of ATP hydrolysed per translo-
cation event remains undeﬁned and the reported range varies
considerably [22,26–29]. One of the major factors precluding
elucidation of the ratio is the inherent diﬃculty in obtaining
accurate transport rates for the hydrophobic substrates of P-
gp in reconstituted proteoliposomes. It has been demonstrated
that both NBDs are capable of binding nucleotide [5,7,17,24],
and recent biochemical evidence indicates that although the
open conformation of P-gp binds two nucleotides, the stable
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mol [30]. In addition, several ‘‘catalytically deﬁcient’’ P-gp mu-
tant isoforms have been demonstrated to trap nucleotide at a
ratio of 1 mol/mol protein [31]. Numerous structural and
molecular modelling investigations with bacterial members of
the ABC transporter family in addition to P-gp suggest that
only a single ATP molecule is trapped during a translocation
cycle [32–34]. Moreover, the long established ‘‘alternating site’’
model of ATP hydrolysis by P-gp indicates that only a single
ATP molecule is hydrolysed per transport event. An alterna-
tive model in which two ATP molecules are hydrolysed in or-
der to transport [125I]iodoarylazidoprazosin [35] has been
presented. Unfortunately, the concentrations of drug and
nucleotide used were only a small fraction of their respective
Kd concentrations, thereby making quantitative predictions
of stoichiometry less rigorous. The thermodynamic transition
model may readily be expanded to incorporate two bound
ATP molecules. In the present review, for simplicity and
weight of available evidence, a single bound molecule of
ATP is depicted and corresponds to the nucleotide that is
hydrolysed during drug translocation.
Is the sequence aﬀected by the presence of drug substrate? In
order for drugs to aﬀect ATP hydrolysis a communication
pathway from binding sites in the TMDs and the NBDs is im-
plicit. Biochemical data demonstrating that ATP binding to
NBDs produces conformational changes in the TMDs has
been obtained from numerous studies (outlined in Table 1)
including (i) accessibility of cysteine residues introduced into
TM6 [36], (ii) altered quenching of intrinsic tryptophan resi-
dues [37], (iii) diﬀerential protease digestion of P-gp [38,39],
(iv) modiﬁed ﬂuorescence of probes incorporated into the
NBDs [15], (v) altered accessibility of an extracellular antibody
epitope [40,41] and (vi) directly through visualisation of struc-
tural rearrangements [42–44]. A consistent observation from
several of these studies is that the presence of transported sub-
strates modiﬁed the magnitude and/or nature of the conforma-
tional change produced by nucleotide. Moreover, these
allosteric communications between NBDs and TMDs produce
functional perturbation that manifests as an acceleration of
ATP hydrolysis [6].
The mechanism of this acceleration is not fully understood
and drugs could alter one or more of the equilibria in the mul-
tistep ATPase activity of P-gp. For example, drugs could
conceivably accelerate either engagement of NBDs (HnATPﬁTable 1
Nucleotide binding and/or hydrolysis events are associated with interdomain
Technique Conformational change upon ATP binding/hydr
Electron microscopy1,2 Altered structure of the TMDs at medium resolu
Fluorescence quenching3 Reduced ﬂuorescence of MIANS-labelled P-gp
(NBD-localized probe)
H/D exchange3 Faster kinetics of deuterium exchange
Intrinsic ﬂuorescence1,2 Increased quenching of tryptophan ﬂuorescence
Limited trypsin digest1,2 Enhanced resistance to trypsin digestion
Pharmacology1 Reduced aﬃnity for drugs
Photolabelling4 Reduced photo-labelling eﬃciency
Site-directed labelling
and crosslinking1,2
Altered packing and orientation of TM helices
UIC2 binding1 Reduced exposure of the UIC2 epitope
Notes. Where marked 1 a pre-hydrolytic state (e.g. bound non-hydrolysab
nucleotide free form. Where marked 2 addition of hydrolysable nucleotide,
change in conformation compared to 1. Where marked 3 the response to
nucleotide hydrolysis, as opposed to nucleotide binding, was required to ideHNATP), or dissociation of ADP post-hydrolysis. The latter
occurs late in the translocation pathway, and drug induced
acceleration at this stage seems intuitively unlikely. Indeed,
studies by Martin et al [45,46], propose that drug is likely to
have dissociated from the transporter prior to generation of
the HNADP intermediate and thus is unlikely to aﬀect the dis-
sociation rate of ADP (Sections 3 and 4). By contrast, drug
binding is likely to stimulate the overall rate of ATP hydrolysis
by promoting engagement of the NBDs; i.e., the rate of the
dHnATPﬁ dHNATP transition. Tombline et al. [31] have pro-
vided strong support using catalytically deﬁcient P-gp isoforms
in which several drugs accelerated the rate of nucleotide trap-
ping within the closed NBD conformation. The kinetics of the
dHnATPﬁ dHNATP transition will need to be signiﬁcantly
more rapid than the HnATPﬁ HNATP transition in order for
P-gp to eﬃciently couple drug translocation with ATP hydro-
lysis. Slow kinetics of the HnATPﬁ HNATP conversion in the
absence of drug substrate is responsible for the ‘‘sluggish’’ rate
of ATP hydrolysis during basal ATPase activity.
Consequently, the reactions shown in the thermodynamic
transition model above (initial binding events) are associated
with ‘‘loading’’ of the transporter and comprise three key ele-
ments; drug association, ATP association and formation of the
closed NBD dimer. The precise order of events is likely to fol-
low the sequence Hnﬁ dHnﬁ dHnATPﬁ dHNATP as shown
by the yellow boxes in the model. Moreover, the acceleration
of NBD dimer formation by transported substrates is an
important step in the coupling process.3. ATP binding provides the initial impetus for translocation
Once P-gp has been ‘‘loaded-up’’ with substrate and nucleo-
tide, the process of binding site reorientation and drug release
begins. Initial hypotheses proposed that hydrolysis of ATP
would provide the impetus for translocation. However, ATP
binding, or binding of non-hydrolysable analogues such as
adenyl-5 0-yl imidodiphosphate (p[NH]ppA) and adenosine 5 0-
O-(3-thiotriphosphate) (ATPcS), per se has been widely dem-
onstrated to induce conformational changes in P-gp from the
NBDs to TMDs and even extracellular loops. Table 1 provides
a summary of the numerous investigations that have demon-
strated these inter-domain communications. Molecular models
of P-gp, based upon structural information [47] suggest thatconformational changes in P-gp
olysis Domain:domain communication identiﬁed Reference
tion NBDM TMD [42,43]
NBDM drug binding sites [51]
Global conformational change [65]
Global conformational change [37]
NBDM ECL [38,66]
NBDM drug binding sites [45,46]
NBDM drug binding sites [21,35,63]
NBDM individual TM helices [36,48]
NBDM ECL [33,67]
le nucleotide) was associated with a conformation distinct from the
or trapping of a post-hydrolytic state, enabled detection of a distinct
hydrolysable nucleotides alone has been reported. Where marked 4
ntify a conformation distinct from the nucleotide free form.
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Fig. 4. Hydrolysis of the bound nucleotide. A subsection of the
thermodynamic transition model during which the nucleotide is
hydrolysed by the NBDs. ‘‘H’’ corresponds to the drug binding sites
within the TMD in the inward facing high aﬃnity conﬁgurations. ‘‘L’’
corresponds to the drug binding sites within the TMD in the outward
facing low aﬃnity conﬁguration. The NBDs are in the engaged (N)
conformations whilst drug is denoted by ‘‘d’’.
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greater than 50 A˚. For example, cryo-electron microscopy of
2D-crystals of P-glycoprotein in nucleotide free and non-
hydrolysable analogue bound states demonstrates altered
architecture of the TMDs [43,44]. Additional studies have been
able to identify speciﬁc TM segments (a-helices) that undergo
changes in environment or spatial organisation in response to
nucleotide binding. Some contrasting information has been
obtained in studies by Loo and Clarke, which have mapped
cross-linking patterns of P-glycoprotein isoforms containing
two introduced cysteine residues in speciﬁc TM segments
[48–50]. For the most part, the pattern of cross-links is identi-
cal in the nucleotide free and p[NH]ppA bound states [49,50],
although there are some ATP-binding dependent conforma-
tional changes documented by this group [48]. Fluorescence
studies of single cysteine containing isoforms of P-glycoprotein
are also consistent with localised changes in the tilt of TM he-
lix 6 subsequent to ATP binding [36].
However, few of these studies are able to provide a descrip-
tion of the molecular alterations in the drug binding sites in-
duced by ATP binding. The possible functional changes (i.e.,
transition intermediate formation) to P-gp in response to
ATP binding are summarised in the thermodynamic transition
model shown in Fig. 3. Indeed, only pharmacological measure-
ments of drug:P-gp interactions are able to directly relate
changes in the aﬃnity of drug interaction with the ATP bound
state. In contrast, ﬂuorescence quenching measurements [51],
and photo-aﬃnity labelling studies [21] provide only indirect
evidence of the change in drug binding in the presence of
nucleotide. Equilibrium radioligand binding assays demon-
strate that non-hydrolysable nucleotides eﬀected a reduction
in the fraction of a transported substrate (vinblastine) bound
to P-gp [45]. This reduction correlated with an almost 10-fold
decrease in the aﬃnity of vinblastine for P-gp in the p[NH]ppA
bound conformation (from 80 nM to 730 nM [46]). Signiﬁ-
cantly, the vanadate-trapped conformation of P-gp showed
identical aﬃnity for vinblastine as the pre-hydrolytic
(p[NH]ppA bound) state, demonstrating that the impetus for
altering the drug binding site is derived from nucleotide bind-
ing, rather than nucleotide hydrolysis [46]. This may be inter-
preted as a reorientation of the vinblastine binding site to theremid
amrof t noi
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Fig. 3. Switch in aﬃnity and orientation of the drug binding sites. A
subsection of the thermodynamic transition model that depicts the
switch in aﬃnity and orientation of the drug binding sites within the
TMDs. ‘‘H’’ corresponds to the drug binding sites within the TMD in
the inward facing high aﬃnity conﬁgurations. ‘‘L’’ corresponds to the
drug binding sites within the TMD in the outward facing low aﬃnity
conﬁguration. The NBDs are in equilibrium between the separate (n)
and engaged (N) conformations whilst drug is denoted by ‘‘d’’.outward facing, low aﬃnity conformation of the TMDs (L); in
other words, the dHNATPﬁ dLNATP transition shown in
Fig. 3.
A question mark does hang over the conformation of the
nucleotide occupancy and oligomerisation of P-gp NBDs at
the ATP binding transition. According to the thermodynamic
transition model (Fig. 4), the two possibilities for this transi-
tion are dHNATPﬁ dLNATP or dHnATPﬁ dLnATP. That is,
the alteration of the drug binding site from high (T) to low
(R) aﬃnity is either coerced by engaged NBDs (N) or disen-
gaged NBDs (n). What is the evidence that NBD engagement
is required for this alteration in drug aﬃnity? As discussed
above, the use of catalytic mutants of mouse P-gp (>85% iden-
tical to human P-gp) has supported the formation of a NBD
engaged dimer containing tightly bound nucleotide (ATP) at
a ratio of 1 mol/mol Pgp [16,20,31,52]. Intriguingly, formation
of this occluded state is drug stimulated arguing for the bind-
ing of drug prior to the tight binding of nucleotide [31]. Thus,
the transition dHNATPﬁ dLNATP is the likely progression,
rather than dHnATPﬁ dLnATP. In the thermodynamic transi-
tion model we suggest that when ATP is represented as the
nucleotide, that this is the tightly occluded nucleotide de-
scribed by Senior and co-workers, which is to undergo hydro-
lysis in subsequent steps (see Fig. 4).
A compelling argument can be made to discount the likeli-
hood of the transition dHnﬁ dLn as this would posit that
the drug-binding site is switched spontaneously to a low aﬃn-
ity conformation, thereby producing translocation in the ab-
sence of nucleotide interaction. Were this scenario to occur,
the energy obtained from nucleotide binding and hydrolysis
is purely concerned with resetting the transporter following
drug translocation. This is unlikely given the demonstrated
interaction between ATP binding and drug binding [45,46].
One cautionary note should be discussed brieﬂy. Although
p[NH]ppA and ATPcS are frequently employed as non-hydro-
lysable analogues of ATP, the precise structures of the three
nucleotides do diﬀer. For example, p[NH]ppA has distinct
bond lengths (P–N = 1.7 A˚ compared to P–O = 1.6 A˚) and
bond angles (P–N–P = 127 compared to P–O–P = 130), as
well as a lower pKa for the terminal phosphate compared to
ATP [53]. These stereochemical diﬀerences could manifest as
non-identical eﬀects of ATP compared to p[NH]ppA, as has
1060 R. Callaghan et al. / FEBS Letters 580 (2006) 1056–1063been seen in the F1-ATPase, where a 100-fold diﬀerence in
apparent aﬃnity for ATP and p[NH]ppA binding has been de-
scribed [54,55]. However, in the case of P-gp such doubts are
tempered by the observation that the potency for inhibition
of ATPase activity by p[NH]ppA is the same as the Km for
ATP hydrolysis [56]. A similar argument can be made to sup-
port the use of ATPcS.4. Drug dissociation and ATP hydrolysis complete the initial
stage of translocation
Evidence discussed in the previous section argues for the
energy obtained from ATP binding (i.e., DG from the
dHnﬁ dHnATPﬁ dHNATP transitions) as the initial impetus,
or switch that facilitates drug translocation. The question re-
mains as to whether the reduction in aﬃnity of the drug bind-
ing sites to the dLNATP conformation correlates with a
reorientation to the extracellular face of the membrane? This
remains unresolved for P-gp. Fluorescence resonance energy
transfer (FRET) measurements determined the distance be-
tween the donor ﬂuorophore drug Hoechst 33342 and the
acceptor ﬂuorophore 7-chloro-4-nitrobenz-2-oxa-1,3-diazole,
which is speculated to bind exclusively to the Walker-A cys-
teine residues in the NBDs [57]. In the ATP free conformation
the measured distance was 38 A˚, and this was slightly reduced
to 34 A˚ in the vanadate-trapped state of P-gp. Both values
suggest that the bound Hoechst 33342 was close to the cyto-
plasmic side of the membrane, apparently incompatible with
a drug binding site reorientation driven by ATP binding or
hydrolysis [57]. Indeed this has been interpreted as a require-
ment for ADP release in the outward orientation of the drug
binding site [57], though see below for a possible alternative
interpretation. No higher resolution structural data exists for
P-gp to address this issue. However, recent data for the Salmo-
nella typhimurium MsbA demonstrated a partially engaged
NBD dimer in a conformation believed to represent a post-
hydrolytic state [14]. This structure contained bound substrate
(lipopolysaccharide) ﬂipped into the outer leaﬂet of the mem-
brane [14]. In addition, data on the closely related bacterial
ABC transporter LmrA, and the distantly related maltose
transporter (detailed descriptions of which are beyond the
scope of this review) clearly agree that the vanadate-trapped
state has already reorientated the substrate (drug or maltose)
binding site [9,58].
So, with the jury still out on the exact correlation between
the low aﬃnity drug binding site and the outward orientation,
the assumption in the Fig. 4 is made that drug release (the
dLNATPﬁ LNATP transition) occurs from an outward (extra-
cellular) facing low aﬃnity intermediate of the TMDs of P-gp.
Once the drug-binding site has been converted to the low aﬃn-
ity conformation (L-conformation) the release, or dissociation,
of drug is rapid and completes its translocation. So does the
hydrolysis of ATP lead directly to the reacquisition of a high
aﬃnity inward facing conformation of the P-gp drug binding
site(s)? It is clear from structural and numerous biochemical
studies, that the hydrolysis of ATP causes signiﬁcant confor-
mational changes in the protein and that this transition inter-
mediate (i.e., ADP Æ Pi bound) is distinct to the ATP bound
form (outlined further in Table 1). However, radioligand bind-
ing studies argue against the proposal that ATP hydrolysis
accompanies a return to the high aﬃnity state since theNADP ÆPi conformation (i.e., vanadate trapped) also displays
low aﬃnity binding of the transported substrate vinblastine,
i.e., LNADP ÆPi, [46]. Further investigations are required to elu-
cidate the molecular nature of the ADP Æ Pi bound intermedi-
ate of P-gp. One possibility is that ATP hydrolysis produces
a reorientation of the drug-binding site to the inward facing
conformation, but does not re-establish the high aﬃnity drug
binding site. This, indeed, would be compatible with the FRET
data discussed above, in which the ADP Æ Vi state of P-gp had
ligand apparently bound at the cytoplasmic face of the
membrane [57].
As mentioned in the previous section, an alternative translo-
cation sequence for P-gp proposes that ATP hydrolysis, rather
than ATP binding, causes the switch in drug binding site(s)
from high to low aﬃnity. This proposal therefore implies that
the dHNATPﬁ dHNADP ÆPiﬁ dLNADP ÆPiﬁ LNADP ÆPi transi-
tion sequence is employed. As a consequence, the ADP Æ Pi
bound intermediate of P-gp (dHNADP ÆPi) would retain bound
drug and that dissociation would only occur following reorien-
tation of this intermediate to the outward facing conformation
dLNADP ÆPi. However, this proposition cannot be reconciled if
the ATP analogue bound, or vanadate trapped intermediates
retain high aﬃnity drug binding. This is clearly not the case
for several P-gp substrates, although some notable exceptions
have been reported. For example, studies with the non-trans-
ported P-gp modulator XR9576 (tariquidar) demonstrate that
ATP binding does not confer a reduction in binding aﬃnity
[59]. This suggests that the communication between the NBDs
and sites capable of drug translocation is diﬀerent to the com-
munication between the NBDs and sites of modulation [45].
This absence of binding site orientation may prevent the trans-
location of XR9576. A comparable observation was made for
the photo-aﬃnity prazosin derivative IAAP [35] and may re-
ﬂect distinct lines of communication depending on either the
site or the properties of the compound. Distinct lines of alloste-
ric communication between the NBDs and diﬀerent function-
alities of the drug-interaction sites are also suggested by
studies of the eﬀect of labelling residues within TM a-helix 6
on drug stimulated ATPase activity [60]. Thus, the exact pro-
gression through the pharmacological cubic ternary model
may be drug dependent and determine whether a drug is trans-
located or not.5. Phosphate dissociation initiates resetting of the NBD and
TMDs
As discussed in Sections 2 and 3, the precise stage of the
translocation cycle at which the drug-binding site is reori-
ented and switches to a low aﬃnity conformation remains
the source of debate [35,45,46,61–63]. However, there is con-
siderable agreement that immediately post ATP hydrolysis,
P-gp displays lower aﬃnity and reduced capacity for drug
binding. This indicates that subsequent events in the catalytic
cycle (i.e., release of phosphate and dissociation of ADP)
mediate resetting of the transition intermediate LNADP ÆPi to
the starting conformation (Hn). Does ADP or inorganic
phosphate dissociate ﬁrst during the resetting phase shown
in Fig. 5? The question was answered by the observation that
vanadate completely inhibits the ATPase activity of P-gp by
stably trapping the protein in a transition state containing
bound Mg Æ ADP [7,35,45,46,52,61–63]. Based on structural
Basal
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TMD Loading
NBD dimerisation
Catalysis &
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Fig. 6. Summary of the overall translocation process. The drug
translocation process for P-gp comprises four distinct stages, (A)
loading of P-gp with drug and nucleotide; (B) reorientation of the drug
binding sites from high to low aﬃnity; (C) nucleotide hydrolysis and
(D) the resetting phase.
HNADP.Pi
LNADP.Pi
HNADP
HnADP Hn
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Fig. 5. Resetting phase of the translocation cycle. The subsection of
the thermodynamic transition model that corresponds to resetting of
P-gp for subsequent drug translocation events. ‘‘H’’ corresponds to the
drug binding sites within the TMD in the inward facing high aﬃnity
conﬁgurations. ‘‘L’’ corresponds to the drug binding sites within the
TMD in the outward facing low aﬃnity conﬁguration. The NBDs are
in equilibrium between the separate (n) and engaged (N) conforma-
tions.
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thought to form a complex with Mg Æ ADP to mimic the
Mg Æ ADP Æ Pi transition intermediate [64]. Thus, the vana-
date ion replaces the released Pi and strongly suggests that
dissociation of Pi precedes that of ADP in the translocation
pathway of P-gp.
The dissociation of phosphate is thought to provide the re-
lease of free energy derived from ATP hydrolysis. This hypoth-
esis was validated by the observation that Pi only binds weakly
to P-gp [7] and implies that the LNADP ÆPiﬁ LNADP pathway
proceeds avidly, with a large negative free energy change. That
this occurs following dissociation of drug substrate conﬁrms
that the energy is used to reset the transporter. What is the re-
leased energy used for? The free energy released may be used
directly to convert drug-binding sites from low aﬃnity out-
ward facing to the high aﬃnity inward facing conformation
(i.e., Hﬁ L). According to this scenario, the energy released
from the dissociation of liberated phosphate destabilises the
outward facing conformation of the TMDs (LNADP). This
destabilised intermediate rapidly undergoes conformational
change to the HNADP species. In turn, the NBDs disengage
(HNADPﬁ HnADP), thus enabling dissociation of the bound
dinucleotide (HnADPﬁ Hn) and the transporter is ready for
a subsequent translocation event.
Alternatively, the energy may be used to disengage the NBDs
from their closed conformation (i.e., Nﬁ n). Thus, phosphate
dissociation from the NBDs (LNADP ÆPiﬁ LNADP) would lead
to a rapid destabilisation of the NBD dimer and the disengage-
ment of the monomers (LNADPﬁ LnADP). Earlier in the trans-
location pathway it was the engagement of the NBDs that
stimulated reorientation of the TMDs from the H to L-confor-
mation. Conversely, it is tempting to view the disengagement of
the NBDs as the stimulus for generating the reverse conforma-
tional change (LnADPﬁ HnADP). ADP readily dissociates
from the HnADP intermediate [31,52] and the transporter is
reset to the basal conformation.
Urbatsch et al. [52] suggested that subsequent release of the
bound Mg Æ ADP requires a slow monomerisation of the
NBDs prior to the rapid dissociation of the dinucleotide.
Ambudkar and co-workers [62] have suggested that the disso-
ciation of Mg Æ ADP represents a rate-limiting step in the
translocation pathway. These two observations also support
the proposal that energy from Pi release is employed in the dis-
engagement of the closed NBD conﬁguration. The precise se-quence of events in the resetting stage of the translocation
pathway is likely to follow one of two routes described above.
Whichever of the two routes is employed in the ﬁnal stages of
the translocation cycle of P-gp has yet to be elucidated. Phar-
macological data again provides evidence that the HnADP con-
formation exists: P-gp containing covalently attached ADP
(i.e., post-release of Pi) has already been converted to the high
aﬃnity drug binding (H) conformation [46]. In addition, this
intermediate could be covalently labelled with [32P]-azido-
ATP in the alternate NBD, suggesting that the NBDs exist
in the disengaged, or open, conformation (Hn). However,
the binding of ATP to the HnADP conformation was not capa-
ble of aﬀecting drug interaction; for instance, accelerating the
dHNATPﬁ dLNATP transition as observed in early stages of
drug translocation. This indicates that the ﬁnal step required
to fully reset P-gp is dissociation of ADP. A corollary of this
likely sequence of events is that the intermediates LN, HN
and Ln are unlikely to be formed.6. Summary
The sequence of events comprising the translocation path-
way of P-gp outlined in this review (Fig. 1 and summary in
Fig. 6) has been based on the considerable amount of available
biochemical and pharmacological information. However,
many key aspects remain unresolved including; the precise
coupling stoichiometry between drug movement and ATP
hydrolysis, and whether the route of coupling is via single or
multiple routes from the drug binding sites. That there are
multiple drug binding sites is well established, however, there
is no detail on their molecular properties or how they discrim-
inate interaction with substrates and modulators. Clearly,
there is a need for further inquisition into the biochemistry
of drug translocation and to provide high-resolution structural
information in order to settle these issues. Once the biological
enigma of multidrug translocation is fully understood we will
be in a position to eﬀectively develop (i) potent, selective P-
gp inhibitors and/or (ii) anti-cancer drugs capable of evading
the unwanted inﬂuence of P-gp.
1062 R. Callaghan et al. / FEBS Letters 580 (2006) 1056–1063Acknowledgements: Research in the Callaghan laboratory was funded
by a Cancer Research UK program grant (SP1861/0401). The authors
thank the following for their discussion and scientiﬁc input over the
course of the last decade: Catherine Martin, Janet Storm, Alice Roth-
nie, Mark Rosenberg and Christopher Higgins.
References
[1] Duraisingh, M.T. and Cowman, A.F. (2005) Contribution of the
pfmdr1 gene to antimalarial drug-resistance. Acta Trop. 94, 181–
190.
[2] Huang, Y. and Sadee, W. (2005) Membrane transporters and
channels in chemoresistance and sensitivity of tumor cells. Cancer
Lett.
[3] Langton, K.P., Henderson, P.J. and Herbert, R.B. (2005)
Antibiotic resistance: multidrug eﬄux proteins, a common trans-
port mechanism? Nat. Prod. Rep. 22, 439–451.
[4] van Veen, H.W. and Callaghan, R. (2003) in: ABC PROTEINS:
From Bacteria to Man (Holland, I.B., Cole, S.P.C., Kuchler, K.
and Higgins, C.F., Eds.), pp. 81–106, Elsevier, London.
[5] al-Shawi, M.K. and Senior, A.E. (1993) Characterization of the
adenosine triphosphatase activity of Chinese hamster P-glyco-
protein. J. Biol. Chem. 268, 4197–4206.
[6] Sarkadi, B., Price, E.M., Boucher, R.C., Germann, U.A. and
Scarborough, G.A. (1992) Expression of the human multi-
drug resistance cDNA in insect cells generates a high activity
drug-stimulated membrane ATPase. J. Biol. Chem. 267,
4854–4858.
[7] Urbatsch, I.L., Sankaran, B., Bhagat, S. and Senior, A.E. (1995)
Both P-glycoprotein nucleotide-binding sites are catalytically
active. J. Biol. Chem. 270, 26956–26961.
[8] Tombline, G., Bartholomew, L.A., Tyndall, G.A., Gimi, K.,
Urbatsch, I.L. and Senior, A.E. (2004) Properties of P-glycopro-
tein with mutations in the ‘‘catalytic carboxylate’’ glutamate
residues. J. Biol. Chem. 279, 46518–46526.
[9] Chen, J., Sharma, S., Quiocho, F.A. and Davidson, A.L. (2001)
Trapping the transition state of an ATP-binding cassette trans-
porter: evidence for a concerted mechanism of maltose transport.
Proc. Natl. Acad. Sci. USA 98, 1525–1530.
[10] Hopfner, K.P., Karcher, A., Shin, D.S., Craig, L., Arthur, L.M.,
Carney, J.P. and Tainer, J.A. (2000) Structural biology of Rad50
ATPase: ATP-driven conformational control in DNA double-
strand break repair and the ABC-ATPase superfamily. Cell 101,
789–800.
[11] Smith, P.C., Karpowich, N., Millen, L., Moody, J.E., Rosen, J.,
Thomas, P.J. and Hunt, J.F. (2002) ATP binding to the motor
domain from an ABC transporter drives formation of a nucle-
otide sandwich dimer. Mol. Cell 10, 139–149.
[12] Chang, G. and Roth, C.B. (2001) Structure of MsbA from E. coli:
a homolog of the multidrug resistance ATP binding cassette
(ABC) transporters. Science 293, 1793–1800.
[13] Chang, G. (2003) Structure of MsbA from Vibrio cholera: a
multidrug resistance ABC transporter homolog in a closed
conformation. J. Mol. Biol. 330, 419–430.
[14] Reyes, C.L. and Chang, G. (2005) Structure of the ABC
transporter MsbA in complex with ADP Æ vanadate and lipopoly-
saccharide. Science 308, 1028–1031.
[15] Liu, R. and Sharom, F.J. (1997) Fluorescence studies on the
nucleotide binding domains of the P-glycoprotein multidrug
transporter. Biochemistry 36, 2836–2843.
[16] Urbatsch, I.L., Gimi, K., Wilke-Mounts, S. and Senior, A.E.
(2000) Conserved walker A Ser residues in the catalytic sites of P-
glycoprotein are critical for catalysis and involved primarily at the
transition state step. J. Biol. Chem. 275, 25031–25038.
[17] Urbatsch, I.L., Beaudet, L., Carrier, I. and Gros, P. (1998)
Mutations in either nucleotide-binding site of P-glycoprotein
(Mdr3) prevent vanadate trapping of nucleotide at both sites.
Biochemistry 37, 4592–4602.
[18] Lerner-Marmarosh, N., Gimi, K., Urbatsch, I.L., Gros, P. and
Senior, A.E. (1999) Large scale puriﬁcation of detergent-
soluble P-glycoprotein from Pichia pastoris cells and charac-
terization of nucleotide binding properties of wild-type, Walker
A, and Walker B mutant proteins. J. Biol. Chem. 274, 34711–
34718.[19] Muller, M. et al. (1996) Altered drug-stimulated ATPase activity
in mutants of the human multidrug resistance protein. J. Biol.
Chem. 271, 1877–1883.
[20] Tombline, G., Bartholomew, L.A., Urbatsch, I.L. and Senior,
A.E. (2004) Combined mutation of catalytic glutamate residues in
the two nucleotide binding domains of P-glycoprotein generates a
conformation that binds ATP and ADP tightly. J. Biol. Chem.
279, 31212–31220.
[21] Ramachandra, M., Ambudkar, S.V., Chen, D., Hrycyna,
C.A., Dey, S., Gottesman, M.M. and Pastan, I. (1998)
Human P-glycoprotein exhibits reduced aﬃnity for substrates
during a catalytic transition state. Biochemistry 37, 5010–
5019.
[22] Shapiro, A.B. and Ling, V. (1995) Reconstitution of drug
transport by puriﬁed P-glycoprotein. J. Biol. Chem. 270, 16167–
16175.
[23] Taylor, A.M. et al. (2001) Detailed characterization of cysteine-
less P-glycoprotein reveals subtle pharmacological diﬀerences in
function from wild-type protein. Br. J. Pharmacol. 134, 1609–
1618.
[24] Urbatsch, I.L., Al-Shawi, M.K. and Senior, A.E. (1994) Charac-
terization of the ATPase activity of puriﬁed Chinese Hamster P-
glycoprotein. Biochemistry 33, 7069–7076.
[25] Sharom, F.J. (1995) Characterization and functional reconstitu-
tion of the multidrug transporter. J. Bioenerg. Biomembr. 27, 15–
22.
[26] Ambudkar, S.V., Cardarelli, C.O., Pashinsky, I. and Stein,
W.D. (1997) Relation between the turnover number for
vinblastine transport and for vinblastine-stimulated ATP
hydrolysis by human P-glycoprotein. J. Biol. Chem. 272,
21160–21166.
[27] Eytan, G.D., Regev, R. and Assaraf, Y.G. (1996) Functional
reconstitution of P-glycoprotein reveals an apparent near stoichi-
ometric drug transport to ATP hydrolysis. J. Biol. Chem. 271,
3172–3178.
[28] Shapiro, A.B. and Ling, V. (1998) Stoichiometry of coupling of
rhodamine 123 transport to ATP hydrolysis by P-glycoprotein.
Eur. J. Biochem. 254, 189–193.
[29] Sharom, F.J., Yu, X. and Doige, C.A. (1993) Functional
reconstitution of drug transport and ATPase activity in proteo-
liposomes containing partially puriﬁed P-glycoprotein. J. Biol.
Chem. 268, 24197–24202.
[30] Delannoy, S., Urbatsch, I.L., Tombline, G., Senior, A.E. and
Vogel, P.D. (2005) Nucleotide binding to the multidrug resistance
P-glycoprotein as studied by ESR spectroscopy. Biochemistry 44,
14010–14019.
[31] Tombline, G., Muharemagic, A., White, L.B. and Senior, A.E.
(2005) Involvement of the ‘‘occluded nucleotide conformation’’ of
p-glycoprotein in the catalytic pathway. Biochemistry 44, 12879–
12886.
[32] Jones, P.M. and George, A.M. (2004) The ABC transporter
structure and mechanism: perspectives on recent research. Cell.
Mol. Life Sci. 61, 1–18.
[33] Locher, K.P. (2004) Structure and mechanism of ABC transport-
ers. Curr. Opin. Struct. Biol. 14, 426–431.
[34] Oloo, E.O. and Tieleman, D.P. (2004) Conformational transitions
induced by the binding of MgATP to the vitamin B12 ATP-
binding cassette (ABC) transporter BtuCD. J. Biol. Chem. 279,
45013–45019.
[35] Sauna, Z.E. and Ambudkar, S.V. (2000) Evidence for a require-
ment for ATP hydrolysis at two distinct steps during a single
turnover of the catalytic cycle of human P-glycoprotein. Proc.
Natl. Acad. Sci. USA 97, 2515–2520.
[36] Rothnie, A., Storm, J., Campbell, J., Linton, K.J., Kerr, I.D. and
Callaghan, R. (2004) The topography of transmembrane segment
six is altered during the catalytic cycle of P-glycoprotein. J. Biol.
Chem. 279, 34913–34921.
[37] Sonveaux, N., Vigano, C., Shapiro, A.B., Ling, V. and Ruyss-
chaert, J.M. (1999) Ligand-mediated tertiary structure changes of
reconstituted P-glycoprotein. A tryptophan ﬂuorescence quench-
ing analysis. J. Biol. Chem. 274, 17649–17654.
[38] Julien, M. and Gros, P. (2000) Nucleotide-induced conforma-
tional changes in P-glycoprotein and in nucleotide binding site
mutants monitored by trypsin sensitivity. Biochemistry 39, 4559–
4568.
R. Callaghan et al. / FEBS Letters 580 (2006) 1056–1063 1063[39] Wang, G., Pincheira, R. and Zhang, J.-T. (1998) Dissection of
drug-binding-induced conformational changes in P-glycoprotein.
Eur. J. Biochem. 255, 383–390.
[40] Mechetner, E.B., Schott, B., Morse, B.S., Stein, W.D., Druley, T.,
Davis, K.A., Tsuruo, T. and Roninson, I.B. (1997) P-glycoprotein
function involves conformational transitions detectable by diﬀer-
ential immunoreactivity. Proc. Natl. Acad. Sci. USA 94, 12908–
12913.
[41] Nagy, H., Goda, K., Arceci, R., Cianfriglia, M., Mechetner, E.
and Szabo Jr., G. (2001) P-glycoprotein conformational changes
detected by antibody competition. Eur. J. Biochem. 268, 2416–
2420.
[42] Rosenberg, M.F., Callaghan, R., Modok, S., Higgins, C.F. and
Ford, R.C. (2005) Three-dimensional structure of P-glycoprotein:
the transmembrane regions adopt an asymmetric conﬁguration in
the nucleotide-bound state. J. Biol. Chem. 280, 2857–2862.
[43] Rosenberg, M.F., Kamis, A.B., Callaghan, R., Higgins, C.F. and
Ford, R.C. (2003) Three-dimensional structures of the mamma-
lian multidrug resistance P-glycoprotein demonstrate major
conformational changes in the transmembrane domains upon
nucleotide binding. J. Biol. Chem. 278, 8294–8299.
[44] Rosenberg, M.F. et al. (2001) Repacking of the transmembrane
domains of P-glycoprotein during the transport ATPase cycle.
EMBO J. 20, 5615–5625.
[45] Martin, C., Berridge, G., Mistry, P., Higgins, C., Charlton, P. and
Callaghan, R. (2000) Drug binding sites on P-glycoprotein are
altered by ATP binding prior to nucleotide hydrolysis. Biochem-
istry 39, 11901–11906.
[46] Martin, C., Higgins, C.F. and Callaghan, R. (2001) The vinblas-
tine binding site adopts high- and low-aﬃnity conformations
during a transport cycle of P-glycoprotein. Biochemistry 40,
15733–15742.
[47] Stenham, D.R., Campbell, J.D., Sansom, M.S., Higgins, C.F.,
Kerr, I.D. and Linton, K.J. (2003) An atomic detail model for the
human ATP binding cassette transporter P-glycoprotein derived
from disulﬁde cross-linking and homology modeling. FASEB J.
17, 2287–2289.
[48] Loo, T.W. and Clarke, D.M. (1997) Drug-stimulated ATPase
activity of human P-glycoprotein requires movement between
transmembrane segments 6 and 12. J. Biol. Chem. 272, 20986–
20989.
[49] Loo, T.W. and Clarke, D.M. (2001) Determining the dimensions
of the drug-binding domain of human P-glycoprotein using thiol
cross-linking compounds as molecular rulers. J. Biol. Chem. 276,
36877–36880.
[50] Loo, T.W. and Clarke, D.M. (2002) Vanadate trapping of
nucleotide at the ATP-binding sites of human multidrug resis-
tance P-glycoprotein exposes diﬀerent residues to the drug-
binding site. Proc. Natl. Acad. Sci. USA 99, 3511–3516.
[51] Liu, R. and Sharom, F.J. (1996) Site-directed ﬂuorescence
labeling of P-glycoprotein on cysteine residues in the nucleotide
binding domains. Biochemistry 35, 11865–11873.
[52] Urbatsch, I.L., Tyndall, G.A., Tombline, G. and Senior, A.E.
(2003) P-glycoprotein catalytic mechanism: studies of the ADP-
vanadate inhibited state. J. Biol. Chem. 278, 23171–23179.[53] Yount, R.G. (1975) ATP analogs. Adv. Enzymol. Relat. Areas
Mol. Biol. 43, 1–56.
[54] Cross, R.L. and Nalin, C.M. (1982) Adenine nucleotide binding
sites on beef heart F1-ATPase. Evidence for three exchangeable
sites that are distinct from three noncatalytic sites. J. Biol. Chem.
257, 2874–2881.
[55] Grubmeyer, C., Cross, R.L. and Penefsky, H.S. (1982) Mecha-
nism of ATP hydrolysis by beef heart mitochondrial ATPase.
Rate constants for elementary steps in catalysis at a single site. J.
Biol. Chem. 257, 12092–12100.
[56] al-Shawi, M.K., Urbatsch, I.L. and Senior, A.E. (1994) Covalent
inhibitors of P-glycoprotein ATPase activity. J. Biol. Chem. 269,
8986–8992.
[57] Qu, Q. and Sharom, F.J. (2002) Proximity of bound Hoechst
33342 to the ATPase catalytic sites places the drug binding site of
P-glycoprotein within the cytoplasmic membrane leaﬂet. Bio-
chemistry 41, 4744–4752.
[58] van Veen, H.W., Margolles, A., Muller, M., Higgins, C.F. and
Konings, W.N. (2000) The homodimeric ATP-binding cassette
transporter LmrA mediates multidrug transport by an alternating
(two-cylinder engine) mechanism. EMBO J. 19, 2503–2514.
[59] Martin, C., Berridge, G., Higgins, C.F., Mistry, P., Charlton, P.
and Callaghan, R. (2000) Communication between multiple drug
binding sites on P-glycoprotein. Mol. Pharmacol. 58, 624–632.
[60] Rothnie, A., Storm, J., McMahon, R., Taylor, A., Kerr, I.D. and
Callaghan, R. (2005) The coupling mechanism of P-glycoprotein
involves residue L339 in the sixth membrane spanning segment.
FEBS Lett. 579, 3984–3990.
[61] Al-Shawi, M.K., Polar, M.K., Omote, H. and Figler, R.A.
(2003) Transition state analysis of the coupling of drug
transport to ATP hydrolysis by P-glycoprotein. J. Biol. Chem.
278, 52629–52640.
[62] Kerr, K.M., Sauna, Z.E. and Ambudkar, S.V. (2001) Correla-
tion between steady-state ATP hydrolysis and vanadate-induced
ADP trapping in human P-glycoprotein. J. Biol. Chem. 276,
8657–8664.
[63] Sauna, Z.E. and Ambudkar, S.V. (2001) Characterization of the
catalytic cycle of ATP hydrolysis by human P-glycoprotein. The
two ATP hydrolysis events in a single catalytic cycle are
kinetically similar but aﬀect diﬀerent functional outcomes. J.
Biol. Chem. 276, 11653–11661.
[64] Mildvan, A.S. (1997) Mechanisms of signaling and related
enzymes. Proteins 29, 401–416.
[65] Sonveaux, N., Shapiro, A.B., Goormaghtigh, E., Ling, V. and
Ruysschaert, J.M. (1996) Secondary and tertiary structure
changes of reconstituted P-glycoprotein. A Fourier transform
attenuated total reﬂection infrared spectroscopy analysis. J. Biol.
Chem. 271, 24617–24624.
[66] Wang, G., Pincheira, R., Zhang, M. and Zhang, J.T. (1997)
Conformational changes of P-glycoprotein by nucleotide binding.
Biochem. J. 328 (Pt 3), 897–904.
[67] Druley, T.E., Stein, W.D. and Roninson, I.B. (2001) Analysis of
MDR1 P-glycoprotein conformational changes in permeabilized
cells using diﬀerential immunoreactivity. Biochemistry 40, 4312–
4322.
